An Overview of Long-Acting GnRH Agonists in Premenopausal Breast Cancer Patients: Survivorship Challenges and Management
Current Oncology · 25.07.2024 · 31 (8) · 4209-4224
DOI: 10.3390/curroncol31080314 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Current Oncology, online erschienen am 25.07.2024. Verfasst von Nathalie LeVasseur und 2 weiteren Autor:innen. Beteiligte Einrichtung: BC Cancer Vancouver Centre, University of British Columbia, Vancouver, BC V5Z 4E6, Canada. Hauptthemen laut MEDLINE: Breast Neoplasms, Premenopause, Gonadotropin-Releasing Hormone, Goserelin. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: TerSera Therapeutics.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Managing breast cancer in premenopausal women poses unique challenges due to its considerable effect on both morbidity and mortality. Goserelin, a gonadotropin-releasing hormone agonist, has emerged among the various modalities as a preferred option for ovarian function suppression, owing to its efficacy in reducing ovarian estrogen production in premenopausal women with hormone receptor-positive breast cancer. Recent studies have affirmed the efficacy and safety of long-acting (LA) goserelin 10.8 mg every 12 weeks, offering comparable outcomes to monthly injections. This flexibility enables personalized treatment approaches, potentially enhancing patient satisfaction. Off-label utilization of goserelin LA surged during the coronavirus disease pandemic, prompting initiatives to broaden its use for breast cancer treatment. Switching to goserelin LA can streamline treatment, boost adherence, and optimize resource utilization. With the recent approval of goserelin 10.8 mg LA by Health Canada on 6 May 2024, for use in breast cancer, Canada is the latest to join over 60 countries worldwide to expand the accepted indications for goserelin LA and ensure its availability to potentially enhance healthcare delivery, patient care, and breast cancer outcomes. Goserelin LA offers premenopausal patients a means to more effectively manage the constraints imposed by breast cancer treatment and its impact on survivorship.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- BC Cancer Vancouver Centre, University of British Columbia, Vancouver, BC V5Z 4E6, Canada.
- Department of Medicine and Department of Oncology, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada.
- Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON M4N 3M5, Canada.
ORCID-Profile: Nathalie LeVasseur, Mita Manna
Förderung
- TerSera Therapeutics
Zitieren
APA
LeVasseur, N., Manna, M., & Jerzak, K. J. (2024). An Overview of Long-Acting GnRH Agonists in Premenopausal Breast Cancer Patients: Survivorship Challenges and Management. Current Oncology, 31(8), 4209-4224. https://doi.org/10.3390/curroncol31080314
Vancouver
LeVasseur N, Manna M, Jerzak KJ. An Overview of Long-Acting GnRH Agonists in Premenopausal Breast Cancer Patients: Survivorship Challenges and Management. Current Oncology. 2024;31(8):4209-4224. doi:10.3390/curroncol31080314
BibTeX
@article{LeVasseur2024,
author = {LeVasseur, Nathalie and Manna, Mita and Jerzak, Katarzyna J},
title = {An Overview of Long-Acting GnRH Agonists in Premenopausal Breast Cancer Patients: Survivorship Challenges and Management},
journal = {Current Oncology},
year = {2024},
volume = {31},
number = {8},
pages = {4209--4224},
doi = {10.3390/curroncol31080314}
}
EUVIMED